Medlab Clinical (ASX: MDC) advances penetration of NanoCelle drug delivery technology, pharmaceutical portfolio (w/ Sean Hall)
Small Caps - A podcast by Small Caps
Categories:
Medlab Clinical (ASX: MDC) chief executive officer Dr Sean Hall joins Small Caps to discuss the company's commercialisation strategy for its NanoCelle drug delivery technology with the European Patent Office recently notifying the company of its intent to grant a patent. Medlab already has a patent in Australia for NanoCelle, with applications also filed in the US, NZ, Singapore and Hong Kong. The company is also progressing its cannabinoid-based drug NanaBis, which is being evaluated in treating cancer-induced bone pain.